Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Published: March 2013

Open Access Gateway

Effective Treatment of Intestinal Behçet's Disease with Long-Term, Low-Dose Clarithromycin

Hakozaki Y. · Mitani K. · Okada C. · Terada H. · Kobari S.

Author affiliations

Department of Internal Medicine, Japan Self Defense Forces Central Hospital, Tokyo, Japan

Corresponding Author

Dr. Yukiya Hakozaki

1-2-24 Ikejiri, Setagaya-ku

Tokyo 154-8532 (Japan)

E-Mail yukiya-ha.ko@nifty.com

Related Articles for ""

Case Rep Gastroenterol 2013;7:122-126

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


A 51-year-old man was referred for body weight loss and lower right abdominal pain. Total colonoscopy revealed discrete and round ulceration at the ileocecal valve, and he was diagnosed with intestinal Behçet's disease (BD). By treatment with glucocorticoid, colchicine and salazosulfapyridine, the symptoms and ulceration were improved, but cessation of glucocorticoid resulted in relapse of ulceration at the terminal ileum. Long-term, low-dose treatment with clarithromycin (CAM) was implemented for chronic respiratory infections. Furthermore, we expected that this CAM treatment would also be effective in BD. During this long-term, low-dose treatment with CAM, discrete ulceration at the terminal ileum was never revealed by follow-up total colonoscopy once or twice per year for 7 years. No reports have described the effectiveness of this treatment in patients with intestinal BD; however, we confirm that long-term treatment with low-dose CAM might have clinical benefits for patients with intestinal BD.

© 2013 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Published: March 2013

Published online: March 13, 2013
Issue release date: January – April

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 0

eISSN: 1662-0631 (Online)

For additional information: http://www.karger.com/CRG

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.